You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA)
|
|---|---|
| Published in |
Molecular Autism, February 2018
|
| DOI | 10.1186/s13229-018-0190-z |
| Pubmed ID | |
| Authors |
Stavros Stivaros, Shruti Garg, Maria Tziraki, Ying Cai, Owen Thomas, Joseph Mellor, Andrew A. Morris, Carly Jim, Karolina Szumanska-Ryt, Laura M Parkes, Hamied A. Haroon, Daniela Montaldi, Nicholas Webb, John Keane, Francisco X. Castellanos, Alcino J. Silva, Sue Huson, Stephen Williams, D. Gareth Evans, Richard Emsley, Jonathan Green, SANTA Consortium |
| Abstract |
Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground by studying statin effects for the first time in younger children with NF1 and co-morbid autism and by using multiparametric imaging outcomes. A single-site triple-blind RCT of simvastatin vs. placebo was done. Assessment (baseline and 12-week endpoint) included peripheral MAPK assay, awake magnetic resonance imaging spectroscopy (MRS; GABA and glutamate+glutamine (Glx)), arterial spin labelling (ASL), apparent diffusion coefficient (ADC), resting state functional MRI, and autism behavioural outcomes (Aberrant Behaviour Checklist and Clinical Global Impression). Thirty subjects had a mean age of 8.1 years (SD 1.8). Simvastatin was well tolerated. The amount of imaging data varied by test. Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12) = - 2.12,p = .055), GABA/Glx ratio (t(12) = - 2.78,p = .016), and reduced grey nuclei Glx (ANCOVAp< 0.05, Mann-Whitneyp< 0.01); (ii) increased ASL perfusion in ventral diencephalon (Mann-Whitneyp < 0.01); and (iii) decreased ADC in cingulate gyrus (Mann-Whitneyp < 0.01). Machine-learning classification of imaging outcomes achieved 79% (p < .05) accuracy differentiating groups at endpoint against chance level (64%,p = 0.25) at baseline. Three of 12 (25%) simvastatin cases compared to none in placebo met 'clinical responder' criteria for behavioural outcome. We show feasibility of peripheral MAPK assay and autism symptom measurement, but the study was not powered to test effectiveness. Multiparametric imaging suggests possible simvastatin effects in brain areas previously associated with NF1 pathophysiology and the social brain network. EU Clinical Trial Register (EudraCT) 2012-005742-38 (www.clinicaltrialsregister.eu). |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 5 | 56% |
| Netherlands | 1 | 11% |
| Unknown | 3 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 56% |
| Practitioners (doctors, other healthcare professionals) | 3 | 33% |
| Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 197 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 197 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 31 | 16% |
| Researcher | 28 | 14% |
| Student > Bachelor | 24 | 12% |
| Student > Ph. D. Student | 12 | 6% |
| Other | 9 | 5% |
| Other | 30 | 15% |
| Unknown | 63 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 18% |
| Psychology | 20 | 10% |
| Neuroscience | 18 | 9% |
| Social Sciences | 8 | 4% |
| Biochemistry, Genetics and Molecular Biology | 7 | 4% |
| Other | 31 | 16% |
| Unknown | 77 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 December 2019.
All research outputs
#3,678,822
of 23,577,654 outputs
Outputs from Molecular Autism
#320
of 684 outputs
Outputs of similar age
#71,469
of 332,107 outputs
Outputs of similar age from Molecular Autism
#13
of 22 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 684 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 28.5. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,107 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.